Slides
Page 1
Aurobindo Pharma Limited Earnings Presentation Q1FY27 AUROBINDO Committed to healthier life ! AUROBINDO Committed to healthier life ! 203 Windsor Center Drive
Page 2
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any part hereof, form the basis of, or be relied on in connection with, any contract, therefore. This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, regulatory and legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance. Aurobindo Pharma Limited undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances. This document is strictly confidential and may not be disclosed, reproduced or redistributed, in whole or in part, to any other person. 2 2
Page 3
Table of Content 3 04 11 14 Q1FY27 Business & Financial Highlights Financial Summary Update on Biosimilars and Biologics Contract Manufacturing 13 Filings Snapshot20
Page 4
Q1FY27 Business & Financial Highlights 4
Page 5
Key Financial Highlights of the Quarter 5 ₹ 9,150 Cr Revenue ₹ 1,924 Cr* EBITDA ₹ 1,032 Cr Net Profit ₹ 7,868 Cr ₹ 1,603 Cr ₹ 824 Cr Y-o-Y growth % 16.3% 20.0% Q1FY27 Q1FY26 25.2% 5*Operating EBITDA excluding one time impact of ₹43 Cr on account of derecognition of lease receivable (Refer Note-11 of Un-audited Consol Results)
Page 6
Revenue of ₹9,150 Cr with 16.3% growth Y-o-Y, driven by strong performance across all business areas, U.S. base business continued to grow driven by volume gains and new launches Business Highlights – Q1FY27 Net Capex of US$ 78 million* primarily towards capability enhancements, new business developments Received final approval for 10 products and launched 10 products in the US market Generated free cash flow of US$ 98mn during the quarter, with a strong net cash position (including investments) of ~US$ 42 million* as on 30-Jun-26, after payment of cash for Lannett acquisition of US$ 247 million and buyback of US$ 85 million *converted at USD:INR rate as on Jun 30th, 2026 Operating EBITDA stood at ₹1,924 Cr with a margin of 21.0% 6
Page 7
1,792 1,603 1,678 1,773 1,801 1,924* Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 903 824 848 910 921 1,032 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Quarterly Performance – Q1FY27 8,382 7,868 8,286 8,646 8,853 9,150 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 EBITDA (₹ Cr.) Cash flows before dividend and buyback (US$ Mn) Revenue (₹ Cr.) PAT (₹ Cr.) 7 7 131 98 57 118 35 98 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 *Operating EBITDA
Page 8
Consolidated Business Performance 8 *includes domestic sales of ₹ 104 Cr in Q1 FY27 against ₹ 75 Cr in Q4 FY26 ₹ Cr Q1FY27 Q1FY26 Y-o-Y (%) Q4FY26 Q-o-Q (%) USA 3,770 3,488 8.1% 3,543 6.4% Europe 2,937 2,338 25.6% 2,795 5.1% Growth Markets* 1,063 772 37.7% 980 8.5% ARV 330 355 -6.9% 328 0.8% Total Formulations 8,101 6,953 16.5% 7,646 6.0% Beta-lactam 800 636 25.7% 918 -12.9% Non Beta-lactam 250 279 -10.6% 290 -13.8% Total API 1,049 916 14.6% 1,208 -13.1% Revenue from operations 9,150 7,868 16.3% 8,853 3.4% 8
Page 9
US Formulations Business Performance Highlights • US revenue in Q1FY27 accounted for 41.2% of consolidated revenue. Ex-gRevlimid the revenue grew by 5% Q-o-Q. The growth was driven by strong volume gains coupled with new launches during the quarter • The company has launched 10 products during the quarter • Received final approval for 10 products during the quarter CommentaryRevenue ex-gRevlimid (US$ Mn) 389 381 399 Q1FY26 Q4FY26 Q1FY27 9 9
Page 10
Europe (EUR Mn) Revenue Break-up by Business Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Cr.) 10 241 261 267 Q1FY26 Q4FY26 Q1FY27 90 107 113 Q1FY26 Q4FY26 Q1FY27 41 36 35 Q1FY26 Q4FY26 Q1FY27 916 1,208 1,049 Q1FY26 Q4FY26 Q1FY27 Europe business posted growth of 11% Y-o-Y with strong performance across all key markets continuing its momentum Growth Markets reported Y-o-Y growth of 25% driven by strong performance across the markets API revenues increased 14.6% Y-o-Y. Sequential performance reflected seasonal softness in the antibiotics portfolio ARV business revenue remained broadly stable at INR 330 Cr with Q-o-Q variation driven by tender opportunities, accounting for 3.6% of consolidated revenue
Page 11
Financial Summary 11
Page 12
Summary Consolidated Profit & Loss Statement 12 ₹ Cr. Q1FY27 Q1FY26 Y-o-Y Chg. (%) Q4FY26 Q-o-Q Chg. (%) Revenue from Operations 9,150 7,868 16.3% 8,853 3.4% Gross Profit 5,523 4,629 19.3% 5,424 1.8% Gross Margin 60.4% 58.8% 153 bps 61.3% -91 bps Overheads -3,599 -3,025 18.9% -3,623 -0.6% Operating EBITDA (before Forex and Other Income) 1,924 1,603 20.0% 1,801 6.8% EBITDA Margin 21.0% 20.4% 60 bps 20.3% 69 bps One time expense on account of derecognition of lease receivable -43 - - - - EBITDA (before Forex and Other Income) 1,881 1,603 17.3% 1,801 4.4% Fx Gain/(Loss) 53 0 n/a -48 n/a Finance Cost -102 -98 4.0% -98 3.5% Depreciation -487 -406 20.0% -479 1.7% Other Income 212 105 n/a 117 80.8% Exceptional items -40 0 n/a 0 n/a PBT before share of profit / (loss) of JV 1,517 1,205 25.9% 1,293 17.3% Tax -483 -383 26.3% -370 30.6% Share of Profit/(Loss) of JV -2 2 n/a -2 -37.0% Profit after Tax 1,032 824 25.2% 921 12.1% Minority Interest 1 1 -2.8% 0 26.2% Net Profit attributable to Owners of the Company 1,033 825 25.2% 921 12.1% Reported EPS 17.86 14.20 25.8% 15.86 12.6% Average Fx rate US$1 = INR 94.53 85.54 91.47 12
Page 13
747 699 726 688 725 800 182 185 117 99 84 87 Mar-25 Jun-25 Sep-25 Dec-25 Mar-26 Jun-26 Working Capital Loan Other Term Loan Net Debt Movement (US$ Mn) Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-23 Mar-24 Mar-25 Mar-26 Jun-26 Closing Rate (INR/USD) 82.170 83.405 85.475 94.835 94.663 Fx Loan restated in INR 4,638 3,994 5,883 6,709 7,472 Rupee Loan 224 2,324 2,065 964 922 Gross Debt 4,862 6,318 7,948 7,673 8,393 Cash Balance & Investments 6,453 6,467 8,307 10,676 8,790 Net Debt/(Net Cash) (1,591) (149) (359) (3,002) (397) Net Debt/(Net Cash) (US$ Mn) (194) (18) (42) (317) (42) Finance Cost# 4.0% 5.1% 5.5% 5.0% 4.8% Income on Investments in INR (cumulative for the period) 148.5 288.3 356.4 331.3 81.4Particulars Q1FY27 Cash Flow from Business after Working Capital & Others 138 Less: Capex Normal/ANDA -40 Free Cash Flow from Business 98 Less: Capex for acquisition of Lannett -247 Less: Buyback -85 Less: Capex for New business / product development -20 Less: Capex for Biosimilars / Biologics CMO -19 Add: Redemption of investments 75 Net Cash Flow after Buyback and Capex -197 Value (US$ Mn) Q1FY27 Opening Cash / (Debt) 228 Free Cash Flow after Dividend -197 Closing Cash / (Debt) 31 Investments 11 Closing Net Cash / (Debt) including Investments 42 # Excluding interest on lease liabilities | Fx Debt and Fx Cash Balance are restated Debt Profile 13 786930 884 13 843 809 887
Page 14
Update on Biosimilars and Biologics Contract Manufacturing 14
Page 15
CuraTeQ Biologics - Q1 FY27 Highlights 15 Regulatory & Filings • ANVISA GMP certification secured: Successfully completed the ANVISA inspection, securing GMP certification for both Drug Substance and Drug Product facilities and supporting future filings in LATAM • Denosumab filed with CHMP/EMA: Filed both FILVIZY (biosimilar to Prolia) and FUGEVY (biosimilar to Xgeva), positioning us to address both the osteoporosis and oncology-supportive-care segments • Omalizumab filing on track for Q3: EMA filing remains on schedule, keeping our respiratory franchise on track to become our third approved segment alongside oncology and bone health. • First U.S. FDA filings imminent: Actively engaging with the FDA ahead of our U.S. filings this year — Omalizumab, Denosumab and Bevacizumab — marking CuraTeQ's entry into the world's largest biosimilars market Commercial Expansion • UK — Full portfolio live: All four MHRA-approved products — Bevqolva, Dazublys, Zefylti and Dyrupeg — are now supplying commercially. • Europe — Multi-country rollout underway: Dazublys, Zefylti and Dyrupeg supplies are live across France, Germany, Portugal, Finland, Hungary, Lithuania and Latvia, with additional country launches already lined up to extend coverage further across the region. • LATAM — Entry secured via Mexico: Bevqolva, Zefylti and Dyrupeg supplies have been initiated in Mexico, establishing our first commercial foothold in Latin America. Partnerships to Scale • Expanded distribution reach across Europe: Distribution agreements with STADA (EU) and Orion (Nordics) to give us scaled commercial coverage in the EU • First footprint in North Africa and CIS: A strategic partnership secured in Algeria covers four products, marking our entry into the North African market and establishing a template for similar partner-led launches in other growth geographies. First approval secured in Uzbekistan with a strategic partner, marking our entry into CIS region. • Building a repeatable growth-market playbook: Additional partnerships are being negotiated in new growth markets. Continued execution across filings, market launches, and distribution alliances
Page 16
Capacity Expansion & Portfolio Broadening 16 Bioreactor Capacity Addition 10,000 L (4 × 2,500 L) mammalian cell-culture bioreactors, with integrated purification suites, being added to existing capacity at CuraTeQ. AuroVaccines Merger Merger of AuroVaccines into CuraTeQ — repurposing vaccine capacity for biosimilars expansion — remains on track. Merger targeted for completion by March 2027. Trastuzumab Portfolio Extension Trastuzumab 600 mg subcutaneous (SC) presentation on track to enter clinical studies in 2026 — broadening the oncology franchise beyond IV formulations with SC presentations. Growth Market Expansion Continued build-out into growth markets in parallel with EU/UK supply ramp-up. Filings in LATAM, South Africa, SEA territories CuraTeQ is investing in new modalities — subcutaneous (SC) formulations and device-combination products such as auto-injectors and pens — positioning for the global healthcare shift from hospital- administered IV treatments to convenient, self-administered care at home. New Device Modalities Building the manufacturing base and pipeline depth to sustain growth into 2030
Page 17
CuraTeQ's Biosimilars Pipeline Status 17 Brand / Code Molecule Segment Stage Status Detail DYRUPEG Pegfilgrastim Oncology Launched EMA, MHRA, HC approved & commercial ZEFYLTI Filgrastim Oncology Launched EMA, MHRA approved & commercial BEVQOLVA Bevacizumab Oncology Launched MHRA, HC, CDSCO approved; Phase 3 ongoing (additional markets) & commercial DAZUBLYS Trastuzumab Oncology Launched EMA, MHRA, CDSCO approved & commercial FUGEVY# / FILVIZY* Denosumab Bone Health Filed Filed with EMA, CDSCO; under review OMAZIJEV Omalizumab Respiratory To Be Filed Phase 3 successful; EMA filing in Q3 2026 BP08 Tocilizumab Autoimmune Pivotal complete Pivotal study complete. Filing in 2027 BP05 Ranibizumab Ophthalmology Phase 3 Phase 3 study in progress — recruiting last few patients BP58 Trastuzumab S.C. Oncology Preclinical/Ph1 On track for Phase 1 study this FY BP27 Undisclosed — Preclinical Preclinical development complete BP25 Undisclosed — Early Dev. Preclinical development complete # FUGEVY is for an orthopedic indication (Fugevy ) And *FILVIZY is for an oncology indication (FILVIZY ) CuraTeQ Biologics — Quarterly Business Update Assets spanning oncology, respiratory, autoimmune and ophthalmology segments
Page 18
Key Next-Wave Products to Sustain Momentum 18 Code Key Indications '25 Rev. '30 Opp. BP31 Plaque Psoriasis, PsA, Ankylosing Spondylitis $6.7B $9.5B BP36 Atopic Dermatitis, Asthma $13.1B $22B BP30 Multiple Myeloma $14.4B $16B BP45 Ulcerative Colitis, Crohn's, Plaque Psoriasis, PsA $17.6B $20B BP51 Ulcerative Colitis, Crohn's, Plaque Psoriasis, PsA $4.2B $5.8B BP29 Multiple Sclerosis $7.2B $6.5B BP41 Lung Cancer (NSCLC, ES-SCLC), HCC, Melanoma $4.4B $8B BP50 Lung Cancer (NSCLC, ES-SCLC), Endometrial, Bladder Cancer $5.9B $8B *Market sizing cited from various third-party market research reports Large addressable markets underpin the post-2026 growth pipeline
Page 19
TheraNym — Our Foray into Biologics Contract Manufacturing 19 Unit 1 — Inaugurated Inaugurated on 3 June 2026. On track to begin qualification activities in November 2026, ahead of first commercial revenues. Unit 2 — Greenfield Build As part of the third product schedule with MSD, ground-breaking completed for a greenfield Drug Substance facility. Full-scale construction begins October 2026, pending clearances. Capacity Unit 2 will add an aggregate 60 kL of mammalian cell-culture bioreactor capacity, plus requisite downstream purification infrastructure. Capital Expenditure Unit 2 is estimated at USD 180 Mn in capex, targeted to be ready for qualification in 2030. The 2030 Vision With Unit 1 and Unit 2's large-scale capacity and the MSD partnership, TheraNym is positioned to become a reliable node in the global biologics supply chain for life-saving therapies by 2030. Outsourcing Growth — Expanding Market The global biologics CDMO/CMO market is growing at a CAGR of over 12%. TheraNym represents Aurobindo's strategic foray into biologics contract manufacturing, as sponsors increasingly outsource complex biologics manufacturing to meet global demand. >12% CAGR — Global Biologics CDMO/CMO Market 7 Anchored by a long-term partnership with Merck Sharp & Dohme (MSD)
Page 20
Filings Snapshot 20
Page 21
US ANDA Filings Snapshot as on 30th June 2026 21 ANDA Filings CNS ARV Gastroenterological SSP & Cephs Oncology & Hormones Anti-Diabetic Controlled Substances Respiratory (incl. Nasal) Ophthalmic Dermatology Penem Injectables Others Total 896 182.3 166 35.0 30 1.5 50 5.5 35 0.7 65 18.6 27 34.6 16 1.0 22 1.7 19 4.1 20 1.3 3 0.2 318 33.5 CVS 125 44.7 Therapy ANDAs Addressable Market Size (US$ Bn)^^ ** Does not include the addressable market of the products approved under PEPFAR; Awaiting final approval includes Tentative Approvals *Tentative Approvals (TAs) include 6 ANDAs approved under PEPFAR ^ Represents dual filing from Eugia 3 and Eugia 5 563 96 0 100 200 300 400 500 600 Approved Awaiting Final Approval 174 63 0 50 100 150 200 250 300 Approved Awaiting Final Approval Specialty & Injectables Aurobindo (Excl. Specialty & Injectables) 737 33 126 0 100 200 300 400 500 600 700 800 Final Approval Tentative Approval* Under Review Unit wise ANDA Fillings **Including acquired ANDAs from Mylan ^^Source: IQVIA MAT Jun’26 Site Details Final Approval Tentative Approval* Under Review Total Unit III Oral Formulations 123 6 5 134 Unit VIB Cephalosporin Orals 15 0 0 15 Unit VII (SEZ) Oral Formulations 165 5 6 176 Unit XII Penicillin Orals & Injectables 12 0 1 13 APL HC I Oral Formulations 30 3 11 44 APL HC III Orals & Topicals 17 0 9 26 APL HC IV Oral Formulations 100 11 20 131 Aurolife & Aurolife – II Orals & Topicals 30 0 13 43 Eugia I Oral & Injectable Formulations 43 7 11 61 Eugia II Penem Injectables 2 0 1 3 Eugia III Injectables & Ophthalmics 108 1 40 149 Eugia SEZ Injectables 11 0 0 11 Eugia Steriles Injectables 3 (2^) 0 3(1^) 6 Aurovitas Oral Formulations 0 0 3 3 Others** 78 0 3 81 Total 737 33 126 896 21
Page 22
Thank You For more information, contact: Investor Relations | Corporate Communications +91 40 6672 1211 ir@aurobindo.com www.aurobindo.com 2222